#cannabisaficionado

Culture

Carly Barton: Pushing Boundaries as the UK’s First Medical Cannabis Patient

Published

on

Carly Barton
Photo | Carly Barton
Advertisement Back2Grow Advertisement

Carly Barton was 23 years old when she suffered a stroke. Anatomically, a stroke is caused by a temporary loss of blood flow to the brain. A simple explanation for an event that can alter the course of thinking, sensation, and perception for the duration of a patient’s life. For some, the aftermath of a stroke can lead to visual hallucinations, the loss of speech, or paralysis. Barton’s stroke, however, left its mark in the form of near continuous pain.

Several years later, it was this pain that landed Barton in a peculiar predicament — what does it take to get the National Health Service (NHS) to cover medical cannabis? Medical cannabis was legalized in the United Kingdom in November of 2018. Although a bit behind the times by North American standards, Home Secretary Sajid Javid called for “swift action” after hearing testimonies from patients and caregivers of those with debilitating and life-threatening illnesses.

True to his word, senior doctor’s were able to write prescriptions for cannabis as of November 01, 2018. And yet, only a few dozen patients have received official prescriptions for the herb. One of these patients is Barton, who has been forking over nearly 400 quid ($527 USD) per month. While politicians were moved to action by stories of epileptic children, it was Barton who received the first medical cannabis prescription in the UK.

And getting one was no easy task.

Gone to the Weeds

Pain is not uncommon after a stroke. While the body itself may not have experienced substantial harm, the brain can continue to send pain messages over and over again, like a noxious memory of an assault that cannot be erased. In Barton’s case, nerve damage garnered her the diagnoses of fibromyalgia and post-stroke neuropathy, which are most commonly treated with opiate pain killers.

“I was prescribed opiates in increasing doses for many years,” Barton explains, “and that leads to quite high doses of fentanyl and morphine.” A doped-induced delirium that lasted for six long years — housebound, imprisoned by one loud and omnipresent sensation, pain.

“Despite the fact that I was on opiates I was still experiencing a huge amount of pain, to the point where I couldn’t breathe, I couldn’t eat, I couldn’t sleep,” says Barton. “I was in my twenties and I needed help to dress and to cut my dinner up and just do really basic life stuff, and that was pretty horrible.”

Before her stroke, Barton was happily entangled in the spring of her life. A twenty-something art lecturer, she spent most of her time buzzing from welding projects to social affairs, a regular “pocket rocket” by her own terms. Still, even given the longstanding stereotypes about artists and cannabis, Barton was far from a stoner-girl hoping that the plant would unlock some hidden creative talent. “I didn’t think it was really me,” she says.

After the stroke, however, life came to a stand-still. In the years after the incident, Barton found herself stuck in a loop. “I was willing to literally try anything to get out of the cycle of just drinking excessive amounts of oral morphine and being on fentanyl all the time,” she says. It was at this point that a friend suggested that Barton try cannabis, a little homegrown which is illegal to cultivate in the UK.

“I had a lot of ideas, those notions, those preconceived notions about cannabis,” Barton explains. For one, she was worried about how the plant might affect her mental health, given that the herb has a reputation for worsening psychiatric ailments like depression and psychosis. And yet, after trying cannabis, Barton found her world turned right-side round within the span of 10 minutes.

Barton took a few puffs. “I went upstairs and my partner said to me, ‘are you alright?’ and I was saying, ‘something’s missing, something’s odd, something’s off.’ I couldn’t put any words to it,” she says. “And then I realized that the feeling that I had was just no pain.”

“It was so alien to me, not being able to feel any pain in my body, that I was confused as to what was happening. As soon as I realized that I couldn’t feel any pain head-to-toe, that was just like the moment when everything changed.”

“I haven’t touched a drop of morphine since that day.”

Becoming the First Medical Cannabis Patient in the UK

For six years, Barton had been stuck in a haze. Unable to perform simple everyday tasks, she spent most of her time lying in bed or lounging about the house. Cannabis, however, gave Barton her life back. It was time to spread the word. Impassioned by the extent of her recovery, Barton teamed up with other patients involved with United Patient’s Alliance, an advocacy group that services around 50,000 patients that currently rely on the black market to supply their medicine.

Founded in 2014, United Patient’s Alliance acts as a microphone for those who lack access to potentially life-saving cannabis medicines. The group lobbies government officials, provides a platform for patients to share their stories and organizes protests and other events across the United Kingdom. In the years leading up to medical cannabis legalization, advocates at the UPA worked tirelessly to connect patients with the policymakers that make decisions regarding their health.

In October of 2018, United Patient’s Alliance got its first major break — the Home Secretary committed to legalization. Barton, who had been consuming cannabis illegally to self-treat her pain condition, jumped at the opportunity to get a legitimate, legal prescription.

There was one major problem, however. Her doctors aligned with the National Health Service wouldn’t break out their prescription pads. Barton was the first medical cannabis patient in the UK to receive a prescription for the natural medicine. And yet, Barton had to fork over some serious cash for a private doctor in order to access medical cannabis. Even with the money, it certainly wasn’t easy.

“I spent months doing a kind of one-woman clinical trial and marking strains out of ten of the different symptoms and keeping a really thorough pain diary and really almost doing an observational trial on myself to determine what works and what didn’t,” she says. She turned these diligent records over to a private doctor, and it was only then that she received her prescription.

And yet, not all medical cannabis patients have the time, money, and where-with-all to keep such diligent records. “For a lot of patients in the UK who have been to doctors, we’ve had massive issues,” says Barton. “Since legalization, there are posts going up in pain clinics across the UK saying ‘don’t even ask about medical cannabis, we won’t be it to you’.”

UK Medical Cannabis Patients Pay an Arm and a Leg

The state of California first legalized medical cannabis in 1996 with Proposition 215. It took another two decades before cannabis reforms were introduced in the United Kingdom. In what some may see as a cruel bit of irony, the United Kingdom is currently the largest producer of medical cannabis in the entire world. In fact, a report from the United Nations International Narcotics Control Board declares that in 2016, over 95 tonnes of medical grade cannabis was produced in the UK, over 44 percent of the market share.

Unfortunately, none of this cannabis is going toward medical patients throughout the country. Instead, this high-quality medicine is used for research and scientific purposes by pharmaceutical companies. Meanwhile, patients like Barton are required to pay out-of-pocket for newly legalized cannabis medicines imported from Bedrocan, a medical cannabis company based in the Netherlands. Between import fees, the cost of the medicine, and the work with the private doctor, Barton raked up a £2,500 (3300 USD) fee in a three-month time period.

“The cost of it is ridiculous,” says Barton. “The cost of my prescription, just for the cannabis bit, was 400 quid for a month. But, once you’ve added on the import company’s cash that they want to import it here from Holland, that’s an extra £1,000. So, it works out at around £700 an ounce.”

Many patients with serious illnesses already face limited incomes and other medical fees, so the cost for private prescriptions creates a huge barrier for patients all over Brittin. For other medical treatments, the British government absorbs most of the cost via the National Health Service. Unfortunately, however, the NHS is not covering newly legalized cannabis medicines. This is something Barton and United Patients Alliance hope to change.

The biggest hurdle? Financial trusts.

“In the UK, each area has an individual trust and they deal with the funding that happens within that geographical area,” Barton explains. “They put limits on what drugs are going to be allowed to be prescribed within that geographical area.”

The goal of these trusts is to manage costs for government-funded health clinics. The money in these trusts comes from taxation, and each trust faces policy restrictions on the amount of money that can be spent on specific types of medicines and treatments.

“The trusts at the moment are refusing to allow doctors under their area to write medical cannabis prescriptions,” says Barton. “They’re literally terrified of opening the floodgates and there being massive ques and not being able to fund them all.”

Should the NHS begin to cover medical cannabis, patients would be able to access their medicine through government-funded sources. For the time being, however, patients are stuck between sticking with the black market or coughing up thousands for regular access to medical-quality products.

For the time being, the black market still seems like the better option.

Cannabis

Minnesota Opens $10.9 Million CanRenew Grant Round for Community Restoration

Minnesota’s next CanRenew round offers community restoration funding, with applications due December 15. The program does not finance cannabis business operations.

Published

on

Minneapolis skyline and a bridge over the Mississippi River

Minnesota has opened another round of CanRenew grants, putting community restoration alongside the business side of cannabis legalization. The Office of Cannabis Management announced the application window on October 22, with submissions due December 15, 2026, at 4:30 p.m. Central Standard Time. For local organizations, the opportunity is to propose a specific investment in communities affected by cannabis prohibition.

The state’s announcement describes a $10.9 million program and anticipated awards ranging from $50,000 to $2 million. OCM expects to select between 15 and 50 organizations. These are planning estimates for a competitive process, rather than commitments to particular applicants or neighborhoods.

A community grant with a defined purpose

CanRenew’s foundation is Minnesota Statutes section 342.70. The law directs funding toward organizations investing in communities where long-term residents qualify as social equity applicants. It describes community investment broadly, including economic development, health-related social conditions, violence prevention, youth development and civil legal aid.

That breadth matters. A cannabis-related public program can serve people who have no intention of opening a dispensary or cultivating a commercial crop. Its connection to legalization lies in the harms it is designed to address and the communities it serves, rather than a requirement to sell cannabis.

The statute also requires applicants to explain community need, expected benefits, costs and their ability to deliver results. Previous experience and community support are central considerations. Youth civic engagement, leadership and youth-led health education receive explicit priority, giving prospective applicants a clearer picture of the program’s public purpose.

Eligibility does not mean business funding

The current request for proposals includes nonprofits, educational institutions, federally recognized Tribes, local governments, private businesses and community groups among potential applicants. Unincorporated groups need an eligible fiscal sponsor. Registration, organizational capacity and the ability to administer the proposed work remain part of eligibility.

However, the applicant’s organizational form does not determine what the money can buy. The RFP excludes using grants to start, operate or expand a business, as well as revenue-generating entrepreneurial activity. A private company’s eligibility to propose community work should therefore not be read as permission to finance its own commercial expansion.

For anyone scanning the headline for startup capital, that distinction is the first useful check. Begin with the project’s purpose, who benefits and how it meets the restoration criteria, before investing time in a budget or assuming a cannabis license is the route into this funding.

Where the community connection comes in

OCM’s program guidance explains that an eligible community need not consist entirely of people individually verified as social equity applicants. The focus is the community served. Its mapping tool can help document several geographic indicators, while projects based on cannabis convictions or policing may need other supporting evidence.

The same guidance distinguishes expanding an eligible existing program from merely paying its current operating expenses. Applicants should identify what additional reach or benefit the proposed grant would create. A familiar program name alone does not explain how a new investment would repair prohibition-related harm in a specific community.

That is a useful lens for residents, too: look for a defined community benefit and an accountable organization, rather than treating the size of an announced grant pool as evidence that a particular local service has already received money.

Different programs serve different needs

The agency’s grants overview separates CanRenew from other Minnesota initiatives. CanGrow supports farmer assistance and loan-related work. Programs administered through the Department of Employment and Economic Development include CanStartUp, CanNavigate and CanTrain, addressing microbusiness lending, navigation assistance and workforce development respectively.

Those names are easy to confuse. Applicants should follow each program’s own current terms and opening dates; an open CanRenew round does not establish that every other initiative is accepting applications. Nor does appearing on the same overview make their eligibility requirements interchangeable.

What to check before applying

Applicants should also plan for administration after an award. The RFP requires a preaward risk assessment and a fully executed agreement before eligible spending begins. Receiving a selection notice does not, by itself, make earlier expenses reimbursable. That timing deserves attention when designing a project’s start date.

The published CanRenew timeline anticipates application review beginning in January 2027, with grant negotiations and project starts later in that year. The application window is therefore the beginning of a selection process, not an announcement that funds have already reached recipients.

Prospective applicants can use OCM’s current application materials to check the work plan, budget and required attachments, and consult the listed information sessions before the deadline. For Minnesota’s cannabis community, this round offers a concrete way to follow legalization beyond store openings: which organizations propose restoration work, which investments are selected and what results they ultimately deliver.

Illustrative stock view of Minneapolis; not a CanRenew-funded project. Photo: Kate L / Pexels.

Continue Reading

Cannabis

Khalifa Kush Plans a Halloween Debut in New York

Khalifa Kush plans to bring KK and Violet Sky flower and pre-rolls to New York on October 31 through a partnership with cultivator and distributor Skyworld.

Published

on

Dried cannabis flowers beside a glass jar

Khalifa Kush is planning a Halloween entrance into New York’s licensed cannabis market. Wiz Khalifa’s brand says sales are set to begin October 31 through a partnership with New York cultivator and distributor Skyworld. As of October 23, that date is still ahead: this is a preview of an announced launch, rather than a report that the products have already reached stores.

The company’s corrected October 14 announcement identifies two starting cultivars, KK and Violet Sky, in flower and pre-roll formats. It describes an initial rollout to 36 dispensaries: seven in New York City and another 29 across Upstate New York and Long Island. These are the brand’s announced distribution plans, not independently confirmed inventory at every location.

A local partner behind a familiar name

Skyworld will handle New York cultivation and distribution, according to the announcement. That makes the local operation central to what consumers eventually buy. A recognizable national brand name tells only part of the story; the cultivation partner, specific batch and store availability are the details shoppers can check when launch day arrives.

Skyworld’s own website describes the business as Indigenous-owned and New York-based, and lists cultivation, processing and distribution license numbers. It identifies SJR Horticulture, LLC as its operator. The company also provides a lab-results section, giving readers a place to look for product documentation rather than relying solely on launch publicity.

Those details establish how Skyworld presents its operation; they do not substitute for checking the state’s licensing resources or a particular product’s certificate. The announcement also corrected its partner’s name from “Skyworld Cannabis” to “Skyworld.” We use the corrected name here.

KK brings a longer backstory

On its KK product page, Khalifa Kush says the original cultivar was developed for Wiz Khalifa’s personal preferences in the early 2010s. The brand describes a period of private use before its first flower sales at Tryke’s Reef dispensaries in the southwestern United States in 2016. That is the company’s account of the cultivar’s commercial history.

It explains why this New York release carries a recognizable identity before any local customer opens a package. The name connects the artist’s cannabis persona with a product line that has moved through multiple state markets. It is also a reminder that a New York debut is a new distribution milestone for an established brand, rather than the creation of an entirely new cultivar.

The broader KK catalog includes formats beyond flower and pre-rolls. That does not mean all of them are included in the New York opening. The dated announcement is the appropriate guide to the initial local offering; later additions should be reported when the company or retailers confirm them.

Violet Sky adds a different genetic branch

The brand’s Violet Sky page describes a selection effort beginning in early 2021 and a cultivar emerging in late 2022. It identifies the cross as Khalifa Mints and GastroPop, and presents Violet Sky as the third addition to its lineup. Those are breeder and brand descriptions, not independent genetic testing by Cannabis Aficionado.

That distinction is especially useful with cultivar coverage. A lineage can help enthusiasts understand how a company positions a release, but it does not tell an individual reader exactly how a product will feel. We have not sampled these New York batches, and the announcement does not establish their final laboratory results, retail pricing or freshness at any particular shop.

Readers following New York’s plant pipeline can also see our coverage of the state’s upcoming nursery application window. Nursery licensing and a branded retail rollout are separate developments, but both make the people and businesses behind the genetics worth paying attention to.

What to check before making the trip

New York’s Office of Cannabis Management consumer guidance recommends checking the dispensary verification tool displayed at licensed storefronts. It also directs consumers to look for the state’s universal symbol on regulated products and a QR code or link to the batch’s certificate of analysis. The agency’s resources are intended for adults 21 and older.

For a planned launch, store-level confirmation is another practical step. Check a participating dispensary’s current menu or contact the store before traveling. An announced statewide rollout does not establish that both cultivars, every package size or every format will be available at the same time in every shop.

For now, the appeal is a clear date and a focused starting lineup: two cultivars, two formats and a named New York partner. The next reporting milestone is October 31 itself, when actual menus and batch information can show how the promised launch translates into a local shopping experience.

Illustrative stock cannabis photograph; not identified as KK, Violet Sky or Skyworld products. Photo: RDNE Stock project / Pexels.

Continue Reading

Cannabis

Section 781 Turns a Hemp Law Into a Cannabis Cultivar and Growers Challenge

Herbies and Blimburn have put a federal provision’s name on a new cannabis line, pairing three versions with a grow-diary competition.

Published

on

Rows of green cannabis plants inside a greenhouse

Cannabis names often borrow from food, music or geography. A new collaboration between Herbies Seeds and Blimburn Seeds takes a more bureaucratic route: Section 781. The line shares its name with a federal provision rewriting the definition of hemp, and its launch comes with a competition built around public grow diaries.

The announcement, published by Cannabis Business Times on October 23, was issued by the company on October 22. It describes three versions of the line and a challenge intended to follow participating plants from seed to harvest. This is a commercial launch with a political reference, rather than a new finding about how the genetics perform.

One name, three different records

The official project’s cultivar page lists Autoflower, Photoperiod and Fast Flowering entries. The records are not identical. They describe different growing timelines and different stated cannabinoid profiles, so a claim attached to one version should not automatically be applied to all three.

For example, the project lists 77–87 days from seed to harvest for the autoflowering version. Its photoperiod record instead lists a flowering period of 56–70 days. Those are different clocks: one begins at the seed stage, while the other describes a particular part of plant development. Putting the numbers beside each other without that distinction can make a comparison more confusing than useful.

The company’s announcement identifies OG Kush and Strawberry Diesel in the original version’s background. That is the breeder’s description of lineage. Cannabis Aficionado has not grown or independently tested these plants, and the announcement should not be read as our confirmation of a particular aroma, effect, yield or laboratory result.

For readers who follow genetics, the interesting part is the invitation to document variation. A diary can show what one grower observed in one setting. Several diaries may reveal a wider range of outcomes. Neither format automatically turns a branded launch into a controlled trial.

The competition is built around documentation

According to the challenge’s entry information, registration is open until December 30, 2026. Participants use the HarvestED platform to keep a diary, and only the Section 781 line is eligible. The published schedule gives different diary-completion dates for the three categories in spring 2027.

The project describes three principal categories, with three winners in each, plus a separate Best Looking Plant award. Its prize page identifies that additional award as limited to the United States and the photoperiod category. Prize availability and eligibility conditions deserve a direct reading; a promotional summary is not a substitute for the organizer’s current rules.

That matters because this is not simply a photo contest with an interchangeable plant in the frame. The challenge ties eligibility to a named commercial line and to records produced over time. Anyone considering it should distinguish the creative appeal of the project from its entry requirements and the laws applying where they live. This article does not establish anyone’s eligibility to purchase, cultivate or enter.

The posted completion schedule sets March 15, 2027 for Auto diaries, March 30 for Fast diaries and May 31 for Photoperiod diaries. Registration and diary completion are therefore separate deadlines. A reader following the project can watch whether entries document the full period promised, rather than judge the entire line from an attractive early photograph.

The distinction between observation and comparison is useful here. To evaluate two diaries, look for clearly identified versions, dates and conditions. A striking image alone does not tell a reader whether two plants were observed at comparable stages or whether their records answer the same question.

What the legal name actually refers to

Section 781 of Public Law 119-37 changes the statutory definition of hemp. Among its provisions is an exclusion concerning viable seeds from plants above a specified total-THC concentration, including THCA. The source plant is part of that wording, which makes the provision more specific than a general question about whether a seed itself contains much THC.

The statute’s name on a seed package does not certify that package’s legal status. Nor does a company’s reading of a provision resolve the separate questions of implementation, documentation, shipping or state law. The launch is best understood as a response to regulatory uncertainty, not a route around it.

That upstream focus also connects with New York’s new nursery licensing window, which addresses a different issue: how licensed businesses supply starting material inside a state-regulated market. Federal hemp definitions and state nursery permissions should not be treated as interchangeable authorizations.

A launch worth following through the diaries

Section 781 is an unusually literal example of cannabis branding absorbing the policy debate around the plant. The next useful evidence will be what the organizers publish, how the competition is administered and what the diaries actually document.

Until then, keep the categories separate: breeder claims, competition rules and legal requirements each answer a different question. The name may be memorable, but the records behind it will be more informative than the label alone.

Illustrative stock cultivation photograph; these plants are not identified as Section 781. Photo: CRYSTALWEED cannabis / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.